Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Orient Pharma Co's Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$253 Mil. Therefore, Orient Pharma Co's EV-to-EBIT ratio for today is 24.47.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Orient Pharma Co's Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$388 Mil. Therefore, Orient Pharma Co's EV-to-EBITDA ratio for today is 15.92.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Orient Pharma Co's Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1,400 Mil. Therefore, Orient Pharma Co's EV-to-Revenue ratio for today is 4.41.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Orient Pharma Co's Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$310 Mil. Therefore, Orient Pharma Co's EV-to-FCF ratio for today is 19.91.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Orient Pharma Co (ROCO:4166) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Orient Pharma Co's current Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$253 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Orient Pharma Co's current Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$388 Mil.
Orient Pharma Co's current Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,400 Mil.
Orient Pharma Co's current Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$360 Mil.
Orient Pharma Co's current Enterprise Value is NT$6,179 Mil.
Orient Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$310 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co Enterprise Value Related Terms
Orient Pharma Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4166 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Orient Pharma Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$6,179 Mil mean?
Orient Pharma Co (ROCO:4166) has a Enterprise Value of NT$6,179 Mil as of Jul. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Orient Pharma Co and its competitors.
Is Orient Pharma Co's Enterprise Value too high?
Orient Pharma Co's current Enterprise Value is NT$6,179 Mil. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Enterprise Value compare to ZTS and UTHR?
Orient Pharma Co's Enterprise Value of NT$6,179 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current Enterprise Value is NT$6,179 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Enterprise Value is NT$6,179 Mil. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Enterprise Value is NT$6,179 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Enterprise Value: NT$6,179 Mil
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
